Vertex Pharmaceuticals Shares Fall 0.22% on 540M Volume Rank 210th as CF Therapy Market Dominance Hits 85.5% by 2034

On September 8, 2025, , , ranking 210th among stocks by volume. . This growth is driven primarily by CFTR modulator therapies, a class where Vertex holds an outsized position. According to the report, , underscoring its entrenched leadership in the therapeutic space.

The analysis highlights sustained demand for Vertex’s specialized treatments, which have redefined CF management through precision medicine. , the concentration of Vertex’s market share suggests limited near-term competition. This dynamic positions the company to benefit from both existing patient cohorts and potential new indications within the CFTR modulator category. However, the report does not quantify specific risks or pipeline advancements that could alter this trajectory.

To build the back-test precisely I need a couple of extra details: 1. Universe • Do you want all U.S.-listed common stocks (NYSE, NASDAQ, AMEX) or a different universe? 2. Trade mechanics • Entry price: today’s close or the next day’s open? • Exit price: next day’s close or next day’s open? 3. Weighting & re-balancing • Equal-weight the 500 names each day (i.e., ? 4. Frictional costs • Should we include transaction costs (commission + slippage)? If so, what rates? 5. Benchmark (optional) • Any benchmark you’d like the results compared against (e.g., S&P 500)? Once I have this information I can generate the daily portfolios, create the 1-day holding signals, .